Mylan to Acquire Pfizer Respiratory Delivery Platform

by Benzinga Staff
November 9, 2011 7:32 AM | 20 seconds read

27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.

Mylan Inc. (Nasdaq: MYL) todayannounced that it has entered into an agreement with Pfizer (NYSE: PFE) for the exclusiveworldwide rights to develop, manufacture and commercialize Pfizer's genericequivalent to GlaxoSmithKline's Advair Diskus and Seretide Diskusincorporating Pfizer's proprietary dry powder inhaler delivery platform.Advair® Diskus and Seretide® Diskus are inhaled fixed-dose combinations ofFluticasone Propionate and Salmeterol delivered via a dry powder inhaler andare used to treat asthma and COPD.

27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: NewsM&A

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.